

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

HCC2157

RRID:CVCL_1261

Type: Cell Line

Proper Citation

RRID:CVCL_1261

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1261

Proper Citation: RRID:CVCL_1261

Description: Cell line HCC2157 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:24094812](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC2157

Synonyms: Hamon Cancer Center 2157

Cross References: CLO:CLO_0003650, EFO:EFO_0001177, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-2340, BioSample:SAMN03470829, BioSample:SAMN03471823, BioSample:SAMN10987607,

cancer cell lines: CVCL_1261, Cell_Model_Passport:SIDM00774, ChEMBL-Cells:CHEMBL3308891, ChEMBL-Targets:CHEMBL2366126, Cosmic:749715, Cosmic:904370, Cosmic:1018472, Cosmic:1235084, Cosmic:1430341, Cosmic:1460236, Cosmic:1473033, Cosmic:1518114, Cosmic:1603210, Cosmic:1995430, Cosmic-CLP:749715, DepMap:ACH-000691, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:749715, GEO:GSM350525, GEO:GSM783938, GEO:GSM847343, GEO:GSM847485, GEO:GSM887048, GEO:GSM888118, GEO:GSM1669854, IARC_TP53:21364, IARC_TP53:22815, IARC_TP53:30204, IGRhCellID:HCC2157, LiGeA:CCLE_003, LINCS_HMS:50581, LINCS_LDP:LCL-1327, PharmacDB:HCC2157_488_2019, PRIDE:PXD030304, Progenetix:CVCL_1261, PubChem_Cell_line:CVCL_1261, Wikidata:Q54881634

ID: CVCL_1261

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260913T003951+0000

Ratings and Alerts

No rating or validation information has been found for HCC2157.

No alerts have been found for HCC2157.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Reinhold WC, et al. (2025) Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer research communications, 5(2), 375.

Harris AR, et al. (2023) Chromatin Accessibility Landscape of Human Triple-negative Breast Cancer Cell Lines Reveals Variation by Patient Donor Ancestry. Cancer research communications, 3(10), 2014.

Jovanovi?? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell systems, 12(5), 401.

Hinohara K, et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer cell, 34(6), 939.